Loading clinical trials...

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Phase Ib/II Investigator Initiated Safety and Efficacy Clinical Trial of Combination Therapy of Intracutaneous GEN0101 With Intravenous Pembrolizmub in Patients Who Have Advanced Melanoma

NCT03818893•Osaka University

View on ClinicalTrials.gov

Summary

This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.

Detailed Description

1\. Primary Objective \& Hypothesis 1. Objective: Efficacy of the combination therapy The combination therapy with intracutaneous injections of GEN0101 + intravenous infusions of Pembrolizumab is given to patients with confirmed SD or unconfirmed PD after anti-PD-1 antibody therapy. When the last subject completes Week 13 (Day 85th), the RECIST v1.1-based antitumor effect is assessed for all the subjects up to Week 17 (Day 113th) and then the ORR is calculated in both treatment groups, which are tested to examine the significant difference to historical data of KEYNOTE-002. 2. Hypothesis: The antitumor effect and the induction of antitumor immunity of the combination therapy would be enhanced. 2\. Secondary Objectives \& Hypothesises 1. Objectives: Efficacy and safety of the combination therapy The combination therapy with intracutaneous injections of GEN0101 + intravenous infusions of Pembrolizumab is given to patients with confirmed SD or unconfirmed PD after anti-PD-1 antibody therapy. When the last subject completed Week 17 (Day 113th), antitumor effect in Week 13 (Day 85th, unconfirmed) and Week 17 (Day 113th, confirmed) is assessed based on RECIST v1.1, irRC, and irRECIST for all subjects and then the ORR is calculated. Likewise, changes in individual tumor sizes in Week 13 (Day 85th, unconfirmed) and Week 17 (Day 113th, confirmed) are measured, and then percent changes in tumor sizes (percent tumor shrinkage or growth) are calculated. In each subject, the induction of antitumor immunity in Week 13 (Day 85th) is investigated with the index of activated NK cells in peripheral blood. When the last subject completed Week 53 (Day 365th), antitumor effect is assessed for all the subjects based on OS and RECIST v1.1, irRC, and irRECIST-based ORR, BOR and PFS, which are tested to examine significant difference to historical data of KEYNOTE-002. When the last subject completed Week 105 (Day 729th), antitumor effect is assessed for all the subjects based on OS and RECIST v1.1, irRC, and irRECIST-based ORR, BOR and PFS, which are tested to examine significant difference to historical data of KEYNOTE-002. On the basis of these results, the antitumor effect and the induction of antitumor immunity of the combination therapy is investigated. These are secondary objectives in the trial. As another secondary objective, AEs are investigated in all the subjects for safety evaluation of the combination therapy until the last subject completed Week 105 (Day 729th). 2. Hypothesis: The antitumor effect and the induction of antitumor immunity of the combination therapy would be enhanced and the safety would be acceptable. 3\. Exploratory Objective Objective: Storage and use of samples for future exploratory evaluation

Eligibility

Age

20 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient will be eligible for this trial if all the following apply:
•1. Patient has given written informed consent by themselves
•2. Patient aged 20 to 85 years at the time of informed consent
•3. Patient has histologically- or cytologically-confirmed melanoma
•4. Patient with a diagnosis of incurable and unresectable, Stage IIIC, IIID or Stage IV advanced melanoma, showing confirmed SD or unconfirmed PD over 12-week treatment with an anti-PD-1 antibody such as nivolumab or Pembrolizumab. To be assigned a status of SD, changes in tumor measurements must be confirmed by consecutive repeat evaluations that should be performed in 4 to 6 weeks after the criteria for response are first met over 12-week of an anti-PD-1 antibody treatment.
•5. Patient has a measurable tumor
•6. Patient has life expectancy of at least 12 weeks after the first dose of investigational product
•7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening
•8. Patient has met the following criteria of clinical laboratory tests at screening (1)White blood cell (WBC) count over 3,000/μL and neutrophil count over 1,500/μL (2)Platelet count over over 75,000/μL (3)Hemoglobin over 8.0 g/dL (4)AST and ALT ≤ 2.5 × upper limit of normal (ULN) (5)Total bilirubin ≤ 2 × ULN (6)Serum creatinine ≤ 2 × ULN
•9. LDH is not higher than the 2-fold of the upper limit of the institutional reference.
+1 more criteria

Exclusion Criteria

•Patient will be excluded from participation if any of the following apply:
•1. Patient has brain metastases. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging\* (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
•2. Patient has showed positive reaction in a prick testing for GEN0101
•3. A patient who has the mutant BRAF gene in a tumor biopsy.
•4. A patient who has current pneumonitis.
•5. Patient concurrently has an active infection requiring systemic therapy.
•6. Patient has received other systemic anticancer therapy than an anti-PD-1 antibody therapy such as nivolumab, Pembrolizumab, or local IFN-beta therapy within 3 weeks before the time of informed consent (or within 6 weeks before the time of the informed consent for a patient who received nitrosourea or mitomycin C)
•7. Patient has received another unapproved drug other than anti-PD-L1 antibody within 4 weeks before the time of informed consent
•8. Patient has intraocular (uveal) melanoma
•9. Patient has or had another malignant tumor than melanoma. However, this criterion does not apply to a patient who has experienced neither recurrence nor metastasis for at least 5 years at the time of informed consent.
+10 more criteria

Locations (7)

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Sapporo Medical University Hospital

Sapporo, Hokkaido, Japan

Kumamoto University Hospital

Kuramoto, Kumamoto, Japan

Shizuoka Cancer Center

Nakatogari, Shizuoka, Japan

Tokyo Medical and Dental University

Bunkyo-ku, Tokyo, Japan

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Osaka International Cancer Institute

Osaka, Japan

Key Dates

Start Date

March 1, 2019

Primary Completion Date

December 31, 2021

Completion Date

June 30, 2022

Last Updated

January 30, 2019

Enrollment

ESTIMATED participants

Conditions

Advanced Melanoma

Interventions

Combination of GEN0101 and Pembrolizmub

DRUG

Contacts

Atsushi Tanemura, Lecture

CONTACT

06-6879-3039 tanemura@derma.med.osaka-u.ac.jp

Yukio Tanaka, Researcher

CONTACT

06-6210-8295 yukiotanaka@dmi.med.osaka-u.ac.jp

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Phase II Trial of LM103 in Advanced Melanoma

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

HS-IT101 Injection in the Treatment of Advanced Melanoma